Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

Microbot Medical Inc.

Microbot Medical received a Buy rating and a $5.50 price target from Roth MKM analyst Kyle Bauser today. Bauser covers the Healthcare sector, focus...

Current Quarter	$-0.06	Next Quarter	$-0.08
Current Year	$-0.31	Next Year	$-0.34
QoQ Growth	-33.3%	YoY Growth	-9.7%
3Y EPS CAGR	+0.0%	Target Price	$8.75
Consensus	Buy	Upside	+263.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MBOT	$2.41	+1.26%	2.77M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MBOT	$2.41	+1.3%	2.77M
3
4
5
6

MBOT

MBOT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Microbot Medical Inc. Data in Excel

Get Microbot Medical Inc. Data in Excel